Metsera Inc.

16.82
-4.33 (-20.47%)
At close: Apr 04, 2025, 3:59 PM
17.18
2.14%
After-hours: Apr 04, 2025, 05:33 PM EDT

Company Description

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity.

The company was incorporated in 2022 and is headquartered in New York, New York.

Metsera Inc.
Metsera Inc. logo
Country United States
IPO Date Jan 31, 2025
Industry Biotechnology
Sector Healthcare
Employees 74
CEO Christopher Whitten Bernard

Contact Details

Address:
3 World Trade Center
New York, New York
United States
Website https://metsera.com

Stock Details

Ticker Symbol MTSR
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0002040807
CUSIP Number n/a
ISIN Number US59267L1070
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Christopher Whitten Bernard Co-Founder, President, Chief Executive Officer & Director
Christopher J. Visioli Co-Founder, Chief Financial Officer & Chief Business Officer
Christopher Todd Cox Chief Legal Officer
Daniel Hoey Chief Technical Operations Officer
Dr. Brian Hubbard Ph.D. Chief Scientific Officer
Dr. Clive A. Meanwell M.D., Ph.D. Co-Founder & Executive Chairman
Dr. Gbolahan Amusa Benz C.F.A., M.D. EVice President of Strategic Finance & Investor Relations
Michael Donovan Chief Design Officer
Nancye Green Chief Experience Officer
Paul L. Berns Co-Founder & Lead Independent Director

Latest SEC Filings

Date Type Title
Jan 31, 2025 SEC STAFF LETTER Filing
Jan 28, 2025 CORRESP Filing
Jan 28, 2025 CORRESP Filing
Jan 28, 2025 CORRESP Filing
Jan 27, 2025 CORRESP Filing
Jan 21, 2025 UPLOAD Filing
Jan 10, 2025 CORRESP Filing
Dec 26, 2024 SEC STAFF LETTER Filing
Dec 26, 2024 UPLOAD Filing
Dec 11, 2024 DRSLTR Filing